Skip to main content
. 2022 Oct 12;13:6002. doi: 10.1038/s41467-022-33267-z

Table 2.

Treatment-related adverse events (TRAEs)

Any Grade Grade 3 Grade 4
Event N % N % N %
Any TRAEs 42 97.7 33 76.7 2 4.7
Hematologic
  Neutrophil count decreased 20 46.5 17 39.5 1 2.3
  Anemia 14 32.6 7 16.3 0 0
  Platelet count decreased 7 16.3 3 7 0 0
  Febrile neutropenia 5 11.6 4 9.3 0 0
Non-hematologic
  Anorexia 17 39.5 2 4.7 0 0
  Nausea 14 32.6 0 0 0 0
  Creatinine increased 13 30.2 2 4.7 0 0
  Diarrhea 13 30.2 1 2.3 0 0
  Hand-foot syndrome 10 23.3 0 0 0 0
  Oral mucositis 10 23.3 1 2.3 0 0
  General weakness 8 18.6 1 2.3 0 0
  Peripheral neuropathy 8 18.6 0 0 0 0
  Abdominal pain 6 14 0 0 0 0
  Fever 6 14 0 0 0 0
  Hypoalbuminemia 2 4.7 1 2.3 0 0
  Hyperkalemia 2 4.7 2 4.7 0 0
  Tinnitus 2 4.7 0 0 0 0
  Thromboembolic event 2 4.7 0 0 1 2.3
Immune-related
  Hypothyroidism 5 11.6 0 0 0 0
  Allergic reaction 4 9.3 1 2.3 0 0
  Pruritus 4 9.3 0 0 0 0
  Colitis 3 7 3 7 0 0
  Adrenal insufficiency 2 4.7 0 0 0 0
  Hyperglycemia 2 4.7 0 0 0 0
  Skin rash 2 4.7 0 0 0 0

One patient died from Grade 5 pneumonia related to disease progression.